Roche’s Tecentriq snags FDA label expansion in type of colon cancer
Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher risk of progression after surgery.
Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher risk of progression after surgery.
Surging demand for injectable therapies (led by GLP‑1s) is exposing a new constraint in drug delivery: not innovation, but the ability to industrialise and manufacture devices at scale.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Australia starts investigation into OpenAI Medicare breach
How DFE Pharma supports confident continuous manufacturing decisions
Industry partnership will determine the success of the transition to low-GWP pMDIs
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory